ArticleBMC microbiology2026
Characterizing the profile transformation of Helicobacter pylori: increased secondary and multidrug resistance following failed eradication in Ningxia, China.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobal antimicrobial resistance to Helicobacter pylori (H. pylori) has escalated significantly.This study aimed to investigate the primary and secondary resistance characteristics of clinical isolates of H. pylori in Ningxia region, and to assess the impact of the number of previous eradication treatment failures on the antibiotic resistance pattern.
resultsThe primary and secondary resistance rates of H. pylori to the six antibiotics were as follows: MET (94.3% vs. 97.5%), CLA (39.8% vs. 74.6%), LEV (40.5% vs. 68.2%), AMO (0.4% vs. 2.5%), FUR (0.0% vs. 0.0%), and TET (0.2% vs. 0.0%). With increasing numbers of treatment failures, the secondary resistance rates of MET, CLA, and LEV all rose significantly, exhibiting a linear correlation (all P < 0.001). In susceptibility testing, the inhibition zone diameter (IZD) of MET consistently fell within the resistant range, while those of CLA and LEV decreased markedly from the susceptible to the resistant range (all P < 0.001). The resistance rates of AMO, TET, and FUR remained consistently low and within the susceptible range; among them, AMO showed a slight reduction in IZD previously treated patients (P < 0.001), though the change was limited. Regarding resistance patterns, Primary drug-resistant strains were predominantly characterized by single (39.9%) and double resistance (35.8%), with the most common combination being MET + CLA/LEV. As treatment failures accumulated, the rate of double drug resistance peaked after the first failure (49.6%), while the rate of multidrug resistance continued to rise-from 21.1% in the treatment-naïve group to 75.0% in the group with ≥ 3 treatment failures (P < 0.001), primarily driven by the MET + CLA + LEV combination.
conclusionsThis study reveals the significant changes pattern of drug resistance of H. pylori in Ningxia region under the background of treatment failure: the resistance rates to MET, CLA and LEV are high, and the secondary resistance increases with the number of treatment failures. The drug resistance pattern shifts from single/double resistance to multiple resistance mainly involving MET + CLA + LEV. In contrast, the resistance rates to AMO, TET and FUR are low and remain stable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.